<DOC>
	<DOC>NCT00004831</DOC>
	<brief_summary>OBJECTIVES: I. Determine the efficacy of cysteine hydrochloride in preventing or decreasing photosensitivity in patients with erythropoietic protoporphyria.</brief_summary>
	<brief_title>Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, crossover study. Patients are randomly assigned to 1 of 2 groups to receive cysteine hydrochloride orally twice daily, 2 capsules with breakfast and 2 with lunch. Group 1 receives cysteine hydrochloride in drug ingestion period 1 followed by placebo in period 2. Group 2 receives placebo in period 1 followed by cysteine hydrochloride in period 2. Both groups ingest placebo for 1 week between the periods. Each drug ingestion period lasts 8 weeks. Follow up phone calls are made at the end of months 1 and 3. All patients schedule follow up visits at the end of each drug ingestion period.</detailed_description>
	<mesh_term>Protoporphyria, Erythropoietic</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Documented erythropoietic protoporphyria Determination of elevated protoporphyrin within the past year Experiencing photosensitivity Prior/Concurrent Therapy No concurrent use of betacarotene Patient Characteristics Other: Not pregnant or nursing Fertile female patients must use effective contraception while on study and for 3 weeks thereafter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 1998</verification_date>
	<keyword>erythropoietic protoporphyria</keyword>
	<keyword>inborn errors of metabolism</keyword>
	<keyword>porphyria</keyword>
	<keyword>rare disease</keyword>
</DOC>